SCHEMBL3604856

SCHEMBL3604856

N=C(N)Nc1nc(-c2ccc3c(c2)CC(=O)N3)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
ALDH1A1 P00352 6/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HTT P42858 2/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
MMP12 P39900 1/20 0.48
PDE3B Q13370 1/20 0.48
PDE3A Q14432 1/20 0.48
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CPT2 P23786 1/20 0.43
CPT1A P50416 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
GRIA1 P42261 1/20 0.43
CACNG8 Q8WXS5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10663004 0.90 MAPT (0.66) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL3607443 0.80 ALDH1A1 (0.68) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL10659225 0.80 MAPT (0.78) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL3610826 0.78 GRIA1 (0.46) ALDH1A1PDE3BPDE3ACYP1A2GRIA1
SCHEMBL18114076 0.78 NPC1 (0.49) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL1559008 0.76 MAPT (0.79) MAPTALDH1A1SMN1; SMN2HTTPOLB
Hydrochloric Acid SCHEMBL5771609 0.75 MAPT (0.77) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL16090361 0.74 MAPT (0.54) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL23548755 0.74 SMN1; SMN2 (0.45) MAPTALDH1A1SMN1; SMN2HTTPOLB
SCHEMBL23548750 0.74 SMN1; SMN2 (0.45) MAPTALDH1A1SMN1; SMN2HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 MAPT 2/4885ALDH1A1 1302/4885SMN1; SMN2 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.